Chugai Pharmaceutical Co., Ltd. (4519.T)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Osamu Okuda
|
President, CEO & Chairman | 272M | -- | 1963 |
|
Mr. Iwaaki Taniguchi
|
Senior Executive Officer, CFO, Head of Finance & Director | -- | -- | 1966 |
|
Toshiya Sasai
|
Executive of Investor Relations Group & Corporate Communications Department | -- | -- | -- |
|
Junichi Takano
|
Head of Marketing & Sales Division | -- | -- | -- |
|
Mr. Shinji Hidaka
|
Executive Vice President | -- | -- | -- |
|
Mr. Tetsuya Yamaguchi
|
Executive Vice President | -- | -- | -- |
|
Mr. Yoshiyuki Yano
|
Executive Vice President | -- | -- | -- |
|
Mr. Kosuke Iijima
|
Head of PHC Solution Department | -- | -- | -- |
|
Dr. Tomoyuki Igawa Ph.D.
|
VP & Head of Research Division | -- | -- | -- |
|
Dr. Kaori Ouchi
|
Executive Vice President | -- | -- | -- |
Chugai Pharmaceutical Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 5,104
Description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Corporate Governance
Upcoming Events
December 29, 2026 at 12:00 AM UTC
Ex-Dividend Date
January 28, 2027 at 6:30 AM UTC
Chugai Pharmaceutical Co., Ltd. Earnings Date
Recent Events
Recent Events Information Not Available
